Advertisement
BMY vs REGN
Which Stock Would AI Choose? Bristol-Myers Squibb (BMY) vs. Regeneron Pharmaceuticals (REGN) Stock Comparison
Key Takeaways
- BMY has outperformed YTD with +11.8% returns versus REGN's +1.9%, driven by strong growth portfolio sales and positive Phase 3 data.
- Both stocks trade at comparable trailing P/E ratios around 17-18, but BMY offers a higher dividend yield of 4.27% compared to REGN's 0.50%.
- BMY's market cap stands at $121B with robust 2026 revenue guidance of $46-47.5B, while REGN at $79B faces Eylea competition but advances in obesity treatments.
- Recent momentum favors BMY amid pipeline wins like Sotyktu approval and mezigdomide data, contrasting REGN's mixed Eylea sales.
- Biotech sector tailwinds support both, but BMY's stability and dividend appeal to value investors, while REGN targets growth in immunology and obesity.
Introduction
Bristol-Myers Squibb (BMY) and Regeneron Pharmaceuticals (REGN) represent key players in the biopharmaceutical sector, with BMY focusing on oncology, immunology, and cardiovascular therapies, and REGN excelling in genetics-driven medicines for eye diseases, allergies, and emerging areas like obesity. This stock comparison analyzes their recent performance, pipeline progress, and market positioning amid competitive pressures and innovation cycles. Traders seeking momentum and income may favor BMY's stability, while growth-oriented investors eye REGN's high-upside catalysts. Understanding relative performance aids in portfolio diversification within biotech's volatile landscape.
BMY Overview and Recent Performance
Bristol-Myers Squibb (BMY), a global biopharma leader, specializes in transformative therapies across oncology, hematology, immunology, and cardiovascular disease. In recent market activity, BMY shares have shown resilience, posting YTD gains of about 11.8% and trading around $59-60, outperforming the S&P 500. Key influences include positive Phase 3 results for oral mezigdomide in relapsed/refractory multiple myeloma and FDA approval of Sotyktu for psoriatic arthritis, bolstering pipeline confidence. Growth portfolio sales rose 15% in recent quarters, offsetting legacy patent challenges, with 2026 revenue guidance of $46-47.5B exceeding estimates. A 4.27% dividend yield and forward P/E near 9.5 enhance appeal amid broader sector recovery.
REGN Overview and Recent Performance
Regeneron Pharmaceuticals (REGN) leverages genetic insights for innovative treatments in ophthalmology, oncology, and immunology, with blockbusters like Eylea and Dupixent. Recent weeks have seen mixed momentum, with YTD returns at +1.9% and shares around $745-760, lagging the market amid Eylea family sales declines due to biosimilar erosion. Positive developments include Phase 3 obesity data for licensed olatorepatide showing up to 19% weight loss and ongoing Dupixent expansions, supporting a promising pipeline. Q4 revenue hit $3.9B with EPS of $11.44 beating estimates, though manufacturing hurdles delayed Eylea HD pre-filled syringe approval. Trailing P/E at 18 reflects growth potential in high-demand areas like immunology.
Trending AI Robots
Tickeron's Trending AI Robots page showcases the platform's top-performing AI trading bots, curated from hundreds available that trade thousands of tickers across diverse strategies, timeframes, and sectors. Only those demonstrating superior adaptation to current market conditions—such as volatility in semiconductors, energy, and aerospace—earn a spot in this dynamic section. Stats highlight impressive ranges: annualized returns from +16.7% to +208%, win rates of 52-95%, and profit factors up to 25.8, with short-term bots (5-60min) excelling in high-momentum plays like SOXL (+109%) and multi-ticker strategies (+129%). These bots employ varied approaches, from pattern recognition to hedging, enabling users to copy proven performers. Explore Tickeron's AI tools to potentially enhance your trading edge in today's markets.
Head-to-Head Comparison
BMY and REGN diverge in business models: BMY's diversified large-cap portfolio emphasizes stable revenue from established drugs like Opdivo and Eliquis, contrasting BMY's growth reliance on Eylea/Dupixent amid competition. Recent momentum tilts to BMY with 11%+ monthly gains from approvals and trial wins, versus REGN's flatter trajectory due to ophthalmology headwinds. Risk factors include BMY's patent cliffs balanced by a deep pipeline, while REGN faces biosimilar pressures but offers obesity catalysts. Sector exposure overlaps in biotech/pharma, yet BMY provides income via dividends, appealing for defensive positioning; REGN suits aggressive growth. Market sentiment favors BMY's undervaluation (forward P/E ~9.5) over REGN's premium, highlighting trade-offs in stability versus upside.
Tickeron AI Verdict
Tickeron's AI currently leans toward BMY based on superior trend consistency, YTD outperformance, pipeline momentum from recent approvals, and attractive valuation with dividend support. REGN's obesity progress adds probabilistic upside, but near-term Eylea challenges temper relative positioning. This favors BMY for balanced exposure in the current environment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BMY is a Buy and REGN is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BMY’s FA Score shows that 2 FA rating(s) are green whileREGN’s FA Score has 1 green FA rating(s).
- BMY’s FA Score: 2 green, 3 red.
- REGN’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BMY’s TA Score shows that 4 TA indicator(s) are bullish while REGN’s TA Score has 2 bullish TA indicator(s).
- BMY’s TA Score: 4 bullish, 6 bearish.
- REGN’s TA Score: 2 bullish, 7 bearish.
Price Growth
BMY (@Pharmaceuticals: Major) experienced а -1.64% price change this week, while REGN (@Biotechnology) price change was -1.70% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.86%. For the same industry, the average monthly price growth was -2.62%, and the average quarterly price growth was +6.54%.
The average weekly price growth across all stocks in the @Biotechnology industry was +1.04%. For the same industry, the average monthly price growth was -3.95%, and the average quarterly price growth was +5.21%.
Reported Earning Dates
BMY is expected to report earnings on Apr 30, 2026.
REGN is expected to report earnings on Apr 29, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-0.86% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
@Biotechnology (+1.04% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| BMY | REGN | BMY / REGN | |
| Capitalization | 120B | 79.2B | 152% |
| EBITDA | 15.2B | 5.82B | 261% |
| Gain YTD | 11.094 | -2.863 | -387% |
| P/E Ratio | 16.94 | 18.05 | 94% |
| Revenue | 48.2B | 14.3B | 337% |
| Total Cash | N/A | 8.61B | - |
| Total Debt | 47.1B | 2.71B | 1,741% |
BMY | REGN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 9 | 12 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 5 Undervalued | 3 Undervalued | |
PROFIT vs RISK RATING 1..100 | 80 | 75 | |
SMR RATING 1..100 | 23 | 53 | |
PRICE GROWTH RATING 1..100 | 46 | 47 | |
P/E GROWTH RATING 1..100 | 68 | 36 | |
SEASONALITY SCORE 1..100 | 75 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
REGN's Valuation (3) in the Biotechnology industry is in the same range as BMY (5) in the Pharmaceuticals Major industry. This means that REGN’s stock grew similarly to BMY’s over the last 12 months.
REGN's Profit vs Risk Rating (75) in the Biotechnology industry is in the same range as BMY (80) in the Pharmaceuticals Major industry. This means that REGN’s stock grew similarly to BMY’s over the last 12 months.
BMY's SMR Rating (23) in the Pharmaceuticals Major industry is in the same range as REGN (53) in the Biotechnology industry. This means that BMY’s stock grew similarly to REGN’s over the last 12 months.
BMY's Price Growth Rating (46) in the Pharmaceuticals Major industry is in the same range as REGN (47) in the Biotechnology industry. This means that BMY’s stock grew similarly to REGN’s over the last 12 months.
REGN's P/E Growth Rating (36) in the Biotechnology industry is in the same range as BMY (68) in the Pharmaceuticals Major industry. This means that REGN’s stock grew similarly to BMY’s over the last 12 months.
| BMY | REGN | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 59% | N/A |
| Stochastic ODDS (%) | 2 days ago 52% | 2 days ago 58% |
| Momentum ODDS (%) | 2 days ago 53% | 2 days ago 46% |
| MACD ODDS (%) | 2 days ago 56% | 2 days ago 70% |
| TrendWeek ODDS (%) | 2 days ago 54% | 2 days ago 54% |
| TrendMonth ODDS (%) | 2 days ago 56% | 2 days ago 61% |
| Advances ODDS (%) | 3 days ago 53% | 11 days ago 64% |
| Declines ODDS (%) | 5 days ago 53% | 2 days ago 51% |
| BollingerBands ODDS (%) | 2 days ago 57% | 2 days ago 51% |
| Aroon ODDS (%) | 2 days ago 54% | 2 days ago 71% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| ION | 60.27 | 0.75 | +1.26% |
| ProShares S&P Global Cor Btty Mtls ETF | |||
| ERTH | 48.82 | 0.60 | +1.24% |
| Invesco MSCI Sustainable Future ETF | |||
| BUFX | 21.51 | N/A | N/A |
| FT Vest Laddered Enh & Mod Buffer ETF | |||
| SMDV | 72.21 | -0.49 | -0.67% |
| ProShares Russell 2000 Dividend Growers | |||
| VFH | 124.56 | -1.32 | -1.05% |
| Vanguard Financials ETF | |||
BMY and
Correlation & Price change
A.I.dvisor indicates that over the last year, BMY has been closely correlated with PFE. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if BMY jumps, then PFE could also see price increases.
| Ticker / NAME | Correlation To BMY | 1D Price Change % | ||
|---|---|---|---|---|
| BMY | 100% | -1.43% | ||
| PFE - BMY | 67% Closely correlated | -1.10% | ||
| MRK - BMY | 63% Loosely correlated | -1.03% | ||
| ABBV - BMY | 58% Loosely correlated | -2.10% | ||
| AMGN - BMY | 58% Loosely correlated | -1.29% | ||
| BIIB - BMY | 54% Loosely correlated | -2.34% | ||
More | ||||
REGN and
Correlation & Price change
A.I.dvisor indicates that over the last year, REGN has been loosely correlated with ARQT. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if REGN jumps, then ARQT could also see price increases.
| Ticker / NAME | Correlation To REGN | 1D Price Change % | ||
|---|---|---|---|---|
| REGN | 100% | -2.47% | ||
| ARQT - REGN | 41% Loosely correlated | -1.47% | ||
| INCY - REGN | 40% Loosely correlated | -0.92% | ||
| SMMT - REGN | 39% Loosely correlated | +1.86% | ||
| BMRN - REGN | 39% Loosely correlated | -3.14% | ||
| IDYA - REGN | 38% Loosely correlated | -1.61% | ||
More | ||||